公开(公告)号：US20240124468A1

公开(公告)日：2024-04-18

申请号：US18257746

申请日：2021-12-15

申请人： CHILDREN'S HOSPITAL MEDICAL CENTER ,  The United States of America, as Represented by the Secretary, Dept. of Health and Human Services ,  KUROME THERAPEUTICS, INC.

发明人： Scott Bryan HOYT ,  Craig Joseph THOMAS ,  Daniel T. STARCZYNOWSKI ,  Patrick Joseph SUTTER ,  Gregory James TAWA ,  Chris James FINOCCHIO ,  Jan Susan ROSENBAUM ,  Gabriel GRACIA MALDONADO

IPC分类号： C07D487/04 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/635 ,  A61P35/02 ,  C07D519/00

CPC分类号： C07D487/04 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/635 ,  A61P35/02 ,  C07D519/00

摘要： Some embodiments of the disclosure include inventive compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.), Additional embodiments provide disease treatment using combinations of the inventive IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.

公开(公告)号：US20220235042A1

公开(公告)日：2022-07-28

申请号：US17587070

申请日：2022-01-28

申请人： CHILDREN'S HOSPITAL MEDICAL CENTER ,  THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES

发明人： Daniel T. STARCZYNOWSKI ,  Craig J. Thomas ,  Garrett Rhyasen ,  Katelyn Melgar ,  Morgan MacKenzie Walker ,  Jian-Kang Jiang

IPC分类号： C07D471/04 ,  A61K31/496

摘要： Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as head and neck squamous cell carcinoma (HNSCC), cancer, blood disorders, etc.). Additional embodiments provide synergistic combinations of a BCL2 inhibitor with an IRAK inhibiting compound, and methods of using same.

公开(公告)号：US20220306621A9

公开(公告)日：2022-09-29

申请号：US16804518

申请日：2020-02-28

申请人： CHILDREN'S HOSPITAL MEDICAL CENTER ,  THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES

发明人： Daniel T. STARCZYNOWSKI ,  Craig J. THOMAS ,  Garrett RHYASEN ,  Katelyn MELGAR ,  Morgan MacKenzie WALKER ,  Jian-kang JIANG

IPC分类号： C07D471/04 ,  A61K31/496

摘要： Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as head and neck squamous cell carcinoma (HNSCC), cancer, blood disorders, etc.). Additional embodiments provide synergistic combinations of a BCL2 inhibitor with an IRAK inhibiting compound, and methods of using same.

公开(公告)号：US20200270242A1

公开(公告)日：2020-08-27

申请号：US16326571

申请日：2017-08-16

申请人： CHILDREN'S HOSPITAL MEDICAL CENTER ,  THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES

发明人： Daniel T. STARCZYNOWSKI ,  Craig J. THOMAS ,  Garrett RHYASEN ,  Katelyn MELGAR ,  Morgan MacKenzie WALKER ,  Jian-kang JIANG

IPC分类号： C07D471/04 ,  A61P35/02

摘要： Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)). Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions (e.g., pharmaceutical compositions) for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as cancer or blood disorders). Further embodiments include methods for making the inventive compounds. Additional embodiments of the invention are also discussed herein.

公开(公告)号：US20240294530A1

公开(公告)日：2024-09-05

申请号：US18258586

申请日：2021-12-23

申请人： CHILDREN'S HOSPITAL MEDICAL CENTER ,  THE UNITED STATES OF AMERICA,ASREPRESENTED BY THE SECRETARY,DEPT. OF HEALTH AND HUMAN SERVICES ,  KUROME THERAPEUTICS, INC.

发明人： Scott Bryan HOYT ,  Craig Joseph THOMAS ,  Daniel T. STARCZYNOWSKI ,  Jan ROSENBAUM ,  Gavriel GRACIA MALDONADO

IPC分类号： C07D487/04 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/541 ,  A61K31/635 ,  A61P35/02 ,  C07D519/00

CPC分类号： C07D487/04 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/541 ,  A61K31/635 ,  A61P35/02 ,  C07D519/00

摘要： Some embodiments of the disclosure include inventive compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.), Additional embodiments provide disease treatment using combinations of the inventive IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.

公开(公告)号：US20230303563A1

公开(公告)日：2023-09-28

申请号：US18018742

申请日：2021-07-31

申请人： CHILDREN'S HOSPITAL MEDICAL CENTER ,  THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN ,  KUROME THERAPEUTICS, INC.

发明人： Scott Bryan HOYT ,  Craig Joseph THOMAS ,  Chris James FINOCCHIO ,  Daniel T. STARCZYNOWSKI ,  Gregory J. TAWA ,  Gabriel GRACIA MALDONADO ,  Jan Susan ROSEBAUM

IPC分类号： C07D471/04 ,  C07D519/00 ,  A61K45/06

CPC分类号： C07D471/04 ,  C07D519/00 ,  A61K45/06

摘要： Some embodiments of the disclosure include disclosed compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the disclosed compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.). Additional embodiments provide disease treatment using combinations of the disclosed IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.

公开(公告)号：US20220213094A1

公开(公告)日：2022-07-07

申请号：US17568023

申请日：2022-01-04

申请人： CHILDREN'S HOSPITAL MEDICAL CENTER ,  THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC

发明人： Daniel T. STARCZYNOWSKI ,  Craig J. THOMAS ,  Garrett RHYASEN ,  Katelyn MELGAR ,  Morgan MacKenzie WALKER ,  Jian-Kang JIANG

IPC分类号： C07D471/04 ,  A61P35/02

摘要： Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)). Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions (e.g., pharmaceutical compositions) for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as cancer or blood disorders). Further embodiments include methods for making the inventive compounds. Additional embodiments of the invention are also discussed herein.